JP2015535252A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015535252A5 JP2015535252A5 JP2015539755A JP2015539755A JP2015535252A5 JP 2015535252 A5 JP2015535252 A5 JP 2015535252A5 JP 2015539755 A JP2015539755 A JP 2015539755A JP 2015539755 A JP2015539755 A JP 2015539755A JP 2015535252 A5 JP2015535252 A5 JP 2015535252A5
- Authority
- JP
- Japan
- Prior art keywords
- indazole
- sulfonamide
- fluoro
- alkyl
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 aralkenyl Chemical group 0.000 claims 47
- 125000000217 alkyl group Chemical group 0.000 claims 36
- 150000003839 salts Chemical class 0.000 claims 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 11
- 125000003710 aryl alkyl group Chemical group 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 125000002252 acyl group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 6
- 125000002877 alkyl aryl group Chemical group 0.000 claims 6
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 6
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 6
- 125000004414 alkyl thio group Chemical group 0.000 claims 6
- 125000003435 aroyl group Chemical group 0.000 claims 6
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims 6
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 6
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims 6
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 6
- 125000005110 aryl thio group Chemical group 0.000 claims 6
- 125000004104 aryloxy group Chemical group 0.000 claims 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 6
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 claims 6
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 150000001408 amides Chemical class 0.000 claims 5
- 125000005368 heteroarylthio group Chemical group 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 208000021722 neuropathic pain Diseases 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 125000006413 ring segment Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- HLIFNQCITGTXJX-DRMXPCRNSA-N 1-[(1r)-1-[2-[2-[(1r,2r)-2-aminocyclohexyl]ethynyl]phenyl]ethyl]-6-fluoro-n-(6-fluoropyridin-2-yl)indazole-5-sulfonamide Chemical compound C1([C@@H](C)N2C3=CC(F)=C(C=C3C=N2)S(=O)(=O)NC=2N=C(F)C=CC=2)=CC=CC=C1C#C[C@H]1CCCC[C@H]1N HLIFNQCITGTXJX-DRMXPCRNSA-N 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- CAIALQMFYYGXBJ-OAHLLOKOSA-N 1-[(1r)-1-[2-(3-aminopropyl)phenyl]ethyl]-6-fluoro-n-(6-fluoropyridin-2-yl)indazole-5-sulfonamide Chemical compound C1([C@@H](C)N2C3=CC(F)=C(C=C3C=N2)S(=O)(=O)NC=2N=C(F)C=CC=2)=CC=CC=C1CCCN CAIALQMFYYGXBJ-OAHLLOKOSA-N 0.000 claims 2
- WCWKMFXFWHIFGR-CQSZACIVSA-N 1-[(1r)-1-[2-(azetidin-3-yl)phenyl]ethyl]-6-fluoro-n-(6-fluoropyridin-2-yl)indazole-5-sulfonamide Chemical compound C1([C@@H](C)N2C3=CC(F)=C(C=C3C=N2)S(=O)(=O)NC=2N=C(F)C=CC=2)=CC=CC=C1C1CNC1 WCWKMFXFWHIFGR-CQSZACIVSA-N 0.000 claims 2
- HLIFNQCITGTXJX-WWEVIYMKSA-N 1-[(1r)-1-[2-[2-[(1s,2s)-2-aminocyclohexyl]ethynyl]phenyl]ethyl]-6-fluoro-n-(6-fluoropyridin-2-yl)indazole-5-sulfonamide Chemical compound C1([C@@H](C)N2C3=CC(F)=C(C=C3C=N2)S(=O)(=O)NC=2N=C(F)C=CC=2)=CC=CC=C1C#C[C@@H]1CCCC[C@@H]1N HLIFNQCITGTXJX-WWEVIYMKSA-N 0.000 claims 2
- HLIFNQCITGTXJX-UHFFFAOYSA-N 1-[1-[2-[2-(2-aminocyclohexyl)ethynyl]phenyl]ethyl]-6-fluoro-n-(6-fluoropyridin-2-yl)indazole-5-sulfonamide Chemical compound N1=CC2=CC(S(=O)(=O)NC=3N=C(F)C=CC=3)=C(F)C=C2N1C(C)C1=CC=CC=C1C#CC1CCCCC1N HLIFNQCITGTXJX-UHFFFAOYSA-N 0.000 claims 2
- DBZJNIHBDORRII-OAHLLOKOSA-N 1-[[(7r)-7-amino-5,6,7,8-tetrahydronaphthalen-1-yl]methyl]-6-fluoro-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound C([C@H](CC1=2)N)CC1=CC=CC=2CN(C1=CC=2F)N=CC1=CC=2S(=O)(=O)NC1=NC=NS1 DBZJNIHBDORRII-OAHLLOKOSA-N 0.000 claims 2
- RHZYYEZFTCJSBE-GFCCVEGCSA-N 6-fluoro-1-[(1r)-1-(1,2,3,4-tetrahydroisoquinolin-8-yl)ethyl]-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound FC=1C=C2N([C@@H](C=3C=4CNCCC=4C=CC=3)C)N=CC2=CC=1S(=O)(=O)NC1=NC=NS1 RHZYYEZFTCJSBE-GFCCVEGCSA-N 0.000 claims 2
- YCZYLEYBYBXZRB-CYBMUJFWSA-N 6-fluoro-1-[(1r)-1-(1,2,3,4-tetrahydroisoquinolin-8-yl)ethyl]-n-(1,3-thiazol-2-yl)indazole-5-sulfonamide Chemical compound FC=1C=C2N([C@@H](C=3C=4CNCCC=4C=CC=3)C)N=CC2=CC=1S(=O)(=O)NC1=NC=CS1 YCZYLEYBYBXZRB-CYBMUJFWSA-N 0.000 claims 2
- ZQLOTXCADLUPOP-LLVKDONJSA-N 6-fluoro-1-[(1r)-1-phenylethyl]-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound C1([C@@H](C)N2C3=CC(F)=C(C=C3C=N2)S(=O)(=O)NC=2SN=CN=2)=CC=CC=C1 ZQLOTXCADLUPOP-LLVKDONJSA-N 0.000 claims 2
- MTXZEXIUQKVXSK-CQSZACIVSA-N 6-fluoro-n-(5-fluoropyridin-2-yl)-1-[(1r)-1-(1,2,3,4-tetrahydroisoquinolin-8-yl)ethyl]indazole-5-sulfonamide Chemical compound FC=1C=C2N([C@@H](C=3C=4CNCCC=4C=CC=3)C)N=CC2=CC=1S(=O)(=O)NC1=CC=C(F)C=N1 MTXZEXIUQKVXSK-CQSZACIVSA-N 0.000 claims 2
- BDXVDLWUWAYQKL-CQSZACIVSA-N 6-fluoro-n-(6-fluoropyridin-2-yl)-1-[(1r)-1-(1,2,3,4-tetrahydroisoquinolin-8-yl)ethyl]indazole-5-sulfonamide Chemical compound FC=1C=C2N([C@@H](C=3C=4CNCCC=4C=CC=3)C)N=CC2=CC=1S(=O)(=O)NC1=CC=CC(F)=N1 BDXVDLWUWAYQKL-CQSZACIVSA-N 0.000 claims 2
- QMJIVIHONRHYGL-MRXNPFEDSA-N 6-fluoro-n-(6-fluoropyridin-2-yl)-1-[(1r)-1-(2-piperidin-4-ylphenyl)ethyl]indazole-5-sulfonamide Chemical compound C1([C@@H](C)N2C3=CC(F)=C(C=C3C=N2)S(=O)(=O)NC=2N=C(F)C=CC=2)=CC=CC=C1C1CCNCC1 QMJIVIHONRHYGL-MRXNPFEDSA-N 0.000 claims 2
- SRBXSJAKGQJETP-MRXNPFEDSA-N 6-fluoro-n-(6-fluoropyridin-2-yl)-1-[(1r)-1-[2-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]ethyl]indazole-5-sulfonamide Chemical compound C1([C@@H](C)N2C3=CC(F)=C(C=C3C=N2)S(=O)(=O)NC=2N=C(F)C=CC=2)=CC=CC=C1C1=CCNCC1 SRBXSJAKGQJETP-MRXNPFEDSA-N 0.000 claims 2
- 125000005021 aminoalkenyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- KVCFFRVMHFWXRQ-GFCCVEGCSA-N n-(5-chloro-1,3-thiazol-2-yl)-6-fluoro-1-[(1r)-1-(1,2,3,4-tetrahydroisoquinolin-8-yl)ethyl]indazole-5-sulfonamide Chemical compound FC=1C=C2N([C@@H](C=3C=4CNCCC=4C=CC=3)C)N=CC2=CC=1S(=O)(=O)NC1=NC=C(Cl)S1 KVCFFRVMHFWXRQ-GFCCVEGCSA-N 0.000 claims 2
- JXVAEAWLORTHQW-GFCCVEGCSA-N n-(5-chloro-1,3-thiazol-2-yl)-6-fluoro-2-[(1r)-1-(1,2,3,4-tetrahydroisoquinolin-8-yl)ethyl]indazole-5-sulfonamide Chemical compound FC1=CC2=NN([C@@H](C=3C=4CNCCC=4C=CC=3)C)C=C2C=C1S(=O)(=O)NC1=NC=C(Cl)S1 JXVAEAWLORTHQW-GFCCVEGCSA-N 0.000 claims 2
- CSCJDGKSKWJIBP-MRXNPFEDSA-N n-(6-fluoropyridin-2-yl)-6-methyl-1-[(1r)-1-(1,2,3,4-tetrahydroisoquinolin-8-yl)ethyl]indazole-5-sulfonamide Chemical compound CC=1C=C2N([C@@H](C=3C=4CNCCC=4C=CC=3)C)N=CC2=CC=1S(=O)(=O)NC1=CC=CC(F)=N1 CSCJDGKSKWJIBP-MRXNPFEDSA-N 0.000 claims 2
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims 1
- BJAWBFPYZRHYLC-UHFFFAOYSA-N 1-(2,3-dihydro-1h-isoindol-4-ylmethyl)-6-fluoro-n-(6-fluoropyridin-2-yl)indazole-5-sulfonamide Chemical compound FC1=CC=CC(NS(=O)(=O)C=2C(=CC=3N(CC=4C=5CNCC=5C=CC=4)N=CC=3C=2)F)=N1 BJAWBFPYZRHYLC-UHFFFAOYSA-N 0.000 claims 1
- AYFXUDMBPRBAPJ-UHFFFAOYSA-N 1-[(2-amino-2,3-dihydro-1h-inden-4-yl)methyl]-6-fluoro-n-(6-fluoropyridin-2-yl)indazole-5-sulfonamide Chemical compound C=12CC(N)CC2=CC=CC=1CN(C1=CC=2F)N=CC1=CC=2S(=O)(=O)NC1=CC=CC(F)=N1 AYFXUDMBPRBAPJ-UHFFFAOYSA-N 0.000 claims 1
- DBZJNIHBDORRII-UHFFFAOYSA-N 1-[(7-amino-5,6,7,8-tetrahydronaphthalen-1-yl)methyl]-6-fluoro-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound C=12CC(N)CCC2=CC=CC=1CN(C1=CC=2F)N=CC1=CC=2S(=O)(=O)NC1=NC=NS1 DBZJNIHBDORRII-UHFFFAOYSA-N 0.000 claims 1
- UKZBXRYSYXZVOR-UHFFFAOYSA-N 1-[(7-amino-5,6,7,8-tetrahydronaphthalen-1-yl)methyl]-6-fluoro-n-(1,3-thiazol-2-yl)indazole-5-sulfonamide Chemical compound C=12CC(N)CCC2=CC=CC=1CN(C1=CC=2F)N=CC1=CC=2S(=O)(=O)NC1=NC=CS1 UKZBXRYSYXZVOR-UHFFFAOYSA-N 0.000 claims 1
- GQZRFXWUYDBETK-UHFFFAOYSA-N 1-[(7-amino-5,6,7,8-tetrahydronaphthalen-1-yl)methyl]-6-methyl-n-(1,3-thiazol-2-yl)indazole-5-sulfonamide Chemical compound CC1=CC=2N(CC=3C=4CC(N)CCC=4C=CC=3)N=CC=2C=C1S(=O)(=O)NC1=NC=CS1 GQZRFXWUYDBETK-UHFFFAOYSA-N 0.000 claims 1
- PXUKNVBPQYBNED-UHFFFAOYSA-N 1-[(7-amino-5,6,7,8-tetrahydronaphthalen-1-yl)methyl]-n-(5-chloro-1,3-thiazol-2-yl)-6-fluoroindazole-5-sulfonamide Chemical compound C=12CC(N)CCC2=CC=CC=1CN(C1=CC=2F)N=CC1=CC=2S(=O)(=O)NC1=NC=C(Cl)S1 PXUKNVBPQYBNED-UHFFFAOYSA-N 0.000 claims 1
- CAIALQMFYYGXBJ-UHFFFAOYSA-N 1-[1-[2-(3-aminopropyl)phenyl]ethyl]-6-fluoro-n-(6-fluoropyridin-2-yl)indazole-5-sulfonamide Chemical compound N1=CC2=CC(S(=O)(=O)NC=3N=C(F)C=CC=3)=C(F)C=C2N1C(C)C1=CC=CC=C1CCCN CAIALQMFYYGXBJ-UHFFFAOYSA-N 0.000 claims 1
- WCWKMFXFWHIFGR-UHFFFAOYSA-N 1-[1-[2-(azetidin-3-yl)phenyl]ethyl]-6-fluoro-n-(6-fluoropyridin-2-yl)indazole-5-sulfonamide Chemical compound N1=CC2=CC(S(=O)(=O)NC=3N=C(F)C=CC=3)=C(F)C=C2N1C(C)C1=CC=CC=C1C1CNC1 WCWKMFXFWHIFGR-UHFFFAOYSA-N 0.000 claims 1
- UKZBXRYSYXZVOR-MRXNPFEDSA-N 1-[[(7r)-7-amino-5,6,7,8-tetrahydronaphthalen-1-yl]methyl]-6-fluoro-n-(1,3-thiazol-2-yl)indazole-5-sulfonamide Chemical compound C([C@H](CC1=2)N)CC1=CC=CC=2CN(C1=CC=2F)N=CC1=CC=2S(=O)(=O)NC1=NC=CS1 UKZBXRYSYXZVOR-MRXNPFEDSA-N 0.000 claims 1
- MNUGLDCSCOZYSQ-QGZVFWFLSA-N 1-[[(7r)-7-amino-5,6,7,8-tetrahydronaphthalen-1-yl]methyl]-6-fluoro-n-(6-fluoropyridin-2-yl)indazole-5-sulfonamide Chemical compound C([C@H](CC1=2)N)CC1=CC=CC=2CN(C1=CC=2F)N=CC1=CC=2S(=O)(=O)NC1=CC=CC(F)=N1 MNUGLDCSCOZYSQ-QGZVFWFLSA-N 0.000 claims 1
- DBZJNIHBDORRII-HNNXBMFYSA-N 1-[[(7s)-7-amino-5,6,7,8-tetrahydronaphthalen-1-yl]methyl]-6-fluoro-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound C([C@@H](CC1=2)N)CC1=CC=CC=2CN(C1=CC=2F)N=CC1=CC=2S(=O)(=O)NC1=NC=NS1 DBZJNIHBDORRII-HNNXBMFYSA-N 0.000 claims 1
- UKZBXRYSYXZVOR-INIZCTEOSA-N 1-[[(7s)-7-amino-5,6,7,8-tetrahydronaphthalen-1-yl]methyl]-6-fluoro-n-(1,3-thiazol-2-yl)indazole-5-sulfonamide Chemical compound C([C@@H](CC1=2)N)CC1=CC=CC=2CN(C1=CC=2F)N=CC1=CC=2S(=O)(=O)NC1=NC=CS1 UKZBXRYSYXZVOR-INIZCTEOSA-N 0.000 claims 1
- MNUGLDCSCOZYSQ-KRWDZBQOSA-N 1-[[(7s)-7-amino-5,6,7,8-tetrahydronaphthalen-1-yl]methyl]-6-fluoro-n-(6-fluoropyridin-2-yl)indazole-5-sulfonamide Chemical compound C([C@@H](CC1=2)N)CC1=CC=CC=2CN(C1=CC=2F)N=CC1=CC=2S(=O)(=O)NC1=CC=CC(F)=N1 MNUGLDCSCOZYSQ-KRWDZBQOSA-N 0.000 claims 1
- HCYBVAJMNZELNV-UHFFFAOYSA-N 1-[[2-(1,2,3,4-tetrahydroisoquinolin-5-yl)phenyl]methyl]-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound C=1C=C2N(CC=3C(=CC=CC=3)C=3C=4CCNCC=4C=CC=3)N=CC2=CC=1S(=O)(=O)NC1=NC=NS1 HCYBVAJMNZELNV-UHFFFAOYSA-N 0.000 claims 1
- KPEIQQYVHAGHIA-UHFFFAOYSA-N 1-[[2-(2,3,4,7-tetrahydro-1h-azepin-5-yl)phenyl]methyl]-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound C=1C=C2N(CC=3C(=CC=CC=3)C=3CCCNCC=3)N=CC2=CC=1S(=O)(=O)NC1=NC=NS1 KPEIQQYVHAGHIA-UHFFFAOYSA-N 0.000 claims 1
- IZQQSZDILYAADY-UHFFFAOYSA-N 1-[[2-(2-amino-1-fluoroethyl)phenyl]methyl]-6-fluoro-n-(6-fluoropyridin-2-yl)indazole-5-sulfonamide Chemical compound NCC(F)C1=CC=CC=C1CN1C2=CC(F)=C(S(=O)(=O)NC=3N=C(F)C=CC=3)C=C2C=N1 IZQQSZDILYAADY-UHFFFAOYSA-N 0.000 claims 1
- KJXORRSVLNZSBG-UHFFFAOYSA-N 1-[[2-(2-aminoethyl)phenyl]methyl]-6-fluoro-n-(6-fluoropyridin-2-yl)indazole-5-sulfonamide Chemical compound NCCC1=CC=CC=C1CN1C2=CC(F)=C(S(=O)(=O)NC=3N=C(F)C=CC=3)C=C2C=N1 KJXORRSVLNZSBG-UHFFFAOYSA-N 0.000 claims 1
- DJUDLAQQIDCWFL-UHFFFAOYSA-N 1-[[2-(3-aminoprop-1-ynyl)phenyl]methyl]-6-fluoro-n-(6-fluoropyridin-2-yl)indazole-5-sulfonamide Chemical compound NCC#CC1=CC=CC=C1CN1C2=CC(F)=C(S(=O)(=O)NC=3N=C(F)C=CC=3)C=C2C=N1 DJUDLAQQIDCWFL-UHFFFAOYSA-N 0.000 claims 1
- DTUSTJJVJJTMGW-UHFFFAOYSA-N 1-[[2-(3-aminopropyl)phenyl]methyl]-6-fluoro-n-(1,3-thiazol-2-yl)indazole-5-sulfonamide Chemical compound NCCCC1=CC=CC=C1CN1C2=CC(F)=C(S(=O)(=O)NC=3SC=CN=3)C=C2C=N1 DTUSTJJVJJTMGW-UHFFFAOYSA-N 0.000 claims 1
- IOCLELURYWJHAP-UHFFFAOYSA-N 1-[[2-(3-aminopropyl)phenyl]methyl]-6-fluoro-n-(6-fluoropyridin-2-yl)indazole-5-sulfonamide Chemical compound NCCCC1=CC=CC=C1CN1C2=CC(F)=C(S(=O)(=O)NC=3N=C(F)C=CC=3)C=C2C=N1 IOCLELURYWJHAP-UHFFFAOYSA-N 0.000 claims 1
- CYDWOBCBPTYJCC-UHFFFAOYSA-N 1-[[2-(4-amino-4-methylpent-1-ynyl)phenyl]methyl]-6-fluoro-n-(6-fluoropyridin-2-yl)indazole-5-sulfonamide Chemical compound CC(C)(N)CC#CC1=CC=CC=C1CN1C2=CC(F)=C(S(=O)(=O)NC=3N=C(F)C=CC=3)C=C2C=N1 CYDWOBCBPTYJCC-UHFFFAOYSA-N 0.000 claims 1
- KXFJWALCQLVADP-UHFFFAOYSA-N 1-[[2-(8-azabicyclo[3.2.1]oct-3-en-3-yl)-4-chlorophenyl]methyl]-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound C=1C(N2)CCC2CC=1C1=CC(Cl)=CC=C1CN(C1=CC=2)N=CC1=CC=2S(=O)(=O)NC1=NC=NS1 KXFJWALCQLVADP-UHFFFAOYSA-N 0.000 claims 1
- CRZNGZBFLFERPO-UHFFFAOYSA-N 1-[[2-(aminomethyl)phenyl]methyl]-6-fluoro-n-(6-fluoropyridin-2-yl)indazole-5-sulfonamide Chemical compound NCC1=CC=CC=C1CN1C2=CC(F)=C(S(=O)(=O)NC=3N=C(F)C=CC=3)C=C2C=N1 CRZNGZBFLFERPO-UHFFFAOYSA-N 0.000 claims 1
- XCWJYPNQTOFDRK-ZZXKWVIFSA-N 1-[[2-[(e)-3-aminoprop-1-enyl]phenyl]methyl]-6-fluoro-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound NC\C=C\C1=CC=CC=C1CN1C2=CC(F)=C(S(=O)(=O)NC=3SN=CN=3)C=C2C=N1 XCWJYPNQTOFDRK-ZZXKWVIFSA-N 0.000 claims 1
- VMTPZTDENTUFFJ-ZZXKWVIFSA-N 1-[[2-[(e)-3-aminoprop-1-enyl]phenyl]methyl]-7-chloro-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound NC\C=C\C1=CC=CC=C1CN1C2=C(Cl)C=C(S(=O)(=O)NC=3SN=CN=3)C=C2C=N1 VMTPZTDENTUFFJ-ZZXKWVIFSA-N 0.000 claims 1
- KENSZPCZGVMJIS-ZZXKWVIFSA-N 1-[[2-[(e)-3-aminoprop-1-enyl]phenyl]methyl]-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound NC\C=C\C1=CC=CC=C1CN1C2=CC=C(S(=O)(=O)NC=3SN=CN=3)C=C2C=N1 KENSZPCZGVMJIS-ZZXKWVIFSA-N 0.000 claims 1
- WHACZBSIVGAAKF-UHFFFAOYSA-N 1-[[4-chloro-2-(1,2,3,4-tetrahydroisoquinolin-5-yl)phenyl]methyl]-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound C=1C=CC=2CNCCC=2C=1C1=CC(Cl)=CC=C1CN(C1=CC=2)N=CC1=CC=2S(=O)(=O)NC1=NC=NS1 WHACZBSIVGAAKF-UHFFFAOYSA-N 0.000 claims 1
- AKCGUMBUZCWBQJ-UHFFFAOYSA-N 1-[[4-chloro-2-(1,2,3,4-tetrahydroisoquinolin-8-yl)phenyl]methyl]-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound C=1C=CC=2CCNCC=2C=1C1=CC(Cl)=CC=C1CN(C1=CC=2)N=CC1=CC=2S(=O)(=O)NC1=NC=NS1 AKCGUMBUZCWBQJ-UHFFFAOYSA-N 0.000 claims 1
- XIPAUKCVSFMVIT-UHFFFAOYSA-N 1-[[4-chloro-2-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]methyl]-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound C=1CNCCC=1C1=CC(Cl)=CC=C1CN(C1=CC=2)N=CC1=CC=2S(=O)(=O)NC1=NC=NS1 XIPAUKCVSFMVIT-UHFFFAOYSA-N 0.000 claims 1
- BTZXXDLJFLQUAK-UHFFFAOYSA-N 1-[[4-chloro-2-(2,3,4,7-tetrahydro-1h-azepin-5-yl)phenyl]methyl]-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound C=1CNCCCC=1C1=CC(Cl)=CC=C1CN(C1=CC=2)N=CC1=CC=2S(=O)(=O)NC1=NC=NS1 BTZXXDLJFLQUAK-UHFFFAOYSA-N 0.000 claims 1
- UYVDFHJCAGJHRN-UHFFFAOYSA-N 1-benzyl-6-fluoro-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound N1=CC=2C=C(S(=O)(=O)NC=3SN=CN=3)C(F)=CC=2N1CC1=CC=CC=C1 UYVDFHJCAGJHRN-UHFFFAOYSA-N 0.000 claims 1
- VAYIKQOWHOXKNF-UHFFFAOYSA-N 1-benzyl-6-fluoro-n-(6-fluoropyridin-2-yl)indazole-5-sulfonamide Chemical compound FC1=CC=CC(NS(=O)(=O)C=2C(=CC=3N(CC=4C=CC=CC=4)N=CC=3C=2)F)=N1 VAYIKQOWHOXKNF-UHFFFAOYSA-N 0.000 claims 1
- GDYQWESMJPXUHN-UHFFFAOYSA-N 1-benzyl-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound C=1C=C2N(CC=3C=CC=CC=3)N=CC2=CC=1S(=O)(=O)NC1=NC=NS1 GDYQWESMJPXUHN-UHFFFAOYSA-N 0.000 claims 1
- YFNMRKXDKJUPQG-UHFFFAOYSA-N 2-[(7-amino-5,6,7,8-tetrahydronaphthalen-1-yl)methyl]-n-(5-chloro-1,3-thiazol-2-yl)-6-fluoroindazole-5-sulfonamide Chemical compound C=12CC(N)CCC2=CC=CC=1CN(N=C1C=C2F)C=C1C=C2S(=O)(=O)NC1=NC=C(Cl)S1 YFNMRKXDKJUPQG-UHFFFAOYSA-N 0.000 claims 1
- MTAODLNXWYIKSO-UHFFFAOYSA-N 2-fluoropyridine Chemical compound FC1=CC=CC=N1 MTAODLNXWYIKSO-UHFFFAOYSA-N 0.000 claims 1
- GKUPWDSSECKUDV-UHFFFAOYSA-N 6-fluoro-1-(1,2,3,4-tetrahydroisoquinolin-8-ylmethyl)-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound FC1=CC=2N(CC=3C=4CNCCC=4C=CC=3)N=CC=2C=C1S(=O)(=O)NC1=NC=NS1 GKUPWDSSECKUDV-UHFFFAOYSA-N 0.000 claims 1
- HNFYOOHRNWTYJO-UHFFFAOYSA-N 6-fluoro-1-(1,2,3,4-tetrahydroisoquinolin-8-ylmethyl)-n-(1,3-thiazol-2-yl)indazole-5-sulfonamide Chemical compound FC1=CC=2N(CC=3C=4CNCCC=4C=CC=3)N=CC=2C=C1S(=O)(=O)NC1=NC=CS1 HNFYOOHRNWTYJO-UHFFFAOYSA-N 0.000 claims 1
- ZQLOTXCADLUPOP-UHFFFAOYSA-N 6-fluoro-1-(1-phenylethyl)-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound N1=CC2=CC(S(=O)(=O)NC=3SN=CN=3)=C(F)C=C2N1C(C)C1=CC=CC=C1 ZQLOTXCADLUPOP-UHFFFAOYSA-N 0.000 claims 1
- RHZYYEZFTCJSBE-LBPRGKRZSA-N 6-fluoro-1-[(1s)-1-(1,2,3,4-tetrahydroisoquinolin-8-yl)ethyl]-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound FC=1C=C2N([C@H](C=3C=4CNCCC=4C=CC=3)C)N=CC2=CC=1S(=O)(=O)NC1=NC=NS1 RHZYYEZFTCJSBE-LBPRGKRZSA-N 0.000 claims 1
- ZQLOTXCADLUPOP-NSHDSACASA-N 6-fluoro-1-[(1s)-1-phenylethyl]-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound C1([C@H](C)N2C3=CC(F)=C(C=C3C=N2)S(=O)(=O)NC=2SN=CN=2)=CC=CC=C1 ZQLOTXCADLUPOP-NSHDSACASA-N 0.000 claims 1
- WDCFIOZXASZLCQ-UHFFFAOYSA-N 6-fluoro-1-[(2-iodophenyl)methyl]-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound N1=CC=2C=C(S(=O)(=O)NC=3SN=CN=3)C(F)=CC=2N1CC1=CC=CC=C1I WDCFIOZXASZLCQ-UHFFFAOYSA-N 0.000 claims 1
- RHZYYEZFTCJSBE-UHFFFAOYSA-N 6-fluoro-1-[1-(1,2,3,4-tetrahydroisoquinolin-8-yl)ethyl]-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound C=1C=CC=2CCNCC=2C=1C(C)N(C1=CC=2F)N=CC1=CC=2S(=O)(=O)NC1=NC=NS1 RHZYYEZFTCJSBE-UHFFFAOYSA-N 0.000 claims 1
- YCZYLEYBYBXZRB-UHFFFAOYSA-N 6-fluoro-1-[1-(1,2,3,4-tetrahydroisoquinolin-8-yl)ethyl]-n-(1,3-thiazol-2-yl)indazole-5-sulfonamide Chemical compound C=1C=CC=2CCNCC=2C=1C(C)N(C1=CC=2F)N=CC1=CC=2S(=O)(=O)NC1=NC=CS1 YCZYLEYBYBXZRB-UHFFFAOYSA-N 0.000 claims 1
- XUAWSGAUNROIKM-UHFFFAOYSA-N 6-fluoro-1-[[2-(1,2,3,4-tetrahydroisoquinolin-5-yl)phenyl]methyl]-n-(1,2,4-thiadiazol-5-yl)indazole-5-sulfonamide Chemical compound FC1=CC=2N(CC=3C(=CC=CC=3)C=3C=4CCNCC=4C=CC=3)N=CC=2C=C1S(=O)(=O)NC1=NC=NS1 XUAWSGAUNROIKM-UHFFFAOYSA-N 0.000 claims 1
- UOKKGTLPBFYZSU-UHFFFAOYSA-N 6-fluoro-1-[[2-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]methyl]-n-(1,3-thiazol-2-yl)indazole-5-sulfonamide Chemical compound N1=CC=2C=C(S(=O)(=O)NC=3SC=CN=3)C(F)=CC=2N1CC1=CC=CC=C1C1=CCNCC1 UOKKGTLPBFYZSU-UHFFFAOYSA-N 0.000 claims 1
- QGLUAAQECRJFMK-UHFFFAOYSA-N 6-fluoro-n-(5-fluoropyridin-2-yl)-1-(1,2,3,4-tetrahydroisoquinolin-8-ylmethyl)indazole-5-sulfonamide Chemical compound N1=CC(F)=CC=C1NS(=O)(=O)C(C(=C1)F)=CC2=C1N(CC=1C=3CNCCC=3C=CC=1)N=C2 QGLUAAQECRJFMK-UHFFFAOYSA-N 0.000 claims 1
- MTXZEXIUQKVXSK-UHFFFAOYSA-N 6-fluoro-n-(5-fluoropyridin-2-yl)-1-[1-(1,2,3,4-tetrahydroisoquinolin-8-yl)ethyl]indazole-5-sulfonamide Chemical compound C=1C=CC=2CCNCC=2C=1C(C)N(C1=CC=2F)N=CC1=CC=2S(=O)(=O)NC1=CC=C(F)C=N1 MTXZEXIUQKVXSK-UHFFFAOYSA-N 0.000 claims 1
- ZVLCBMOKPBYNBF-UHFFFAOYSA-N 6-fluoro-n-(6-fluoropyridin-2-yl)-1-(1,2,3,4-tetrahydroisoquinolin-8-ylmethyl)indazole-5-sulfonamide Chemical compound FC1=CC=CC(NS(=O)(=O)C=2C(=CC=3N(CC=4C=5CNCCC=5C=CC=4)N=CC=3C=2)F)=N1 ZVLCBMOKPBYNBF-UHFFFAOYSA-N 0.000 claims 1
- UBGLVEIJGVQXPA-UHFFFAOYSA-N 6-fluoro-n-(6-fluoropyridin-2-yl)-1-[(2-iodophenyl)methyl]indazole-5-sulfonamide Chemical compound FC1=CC=CC(NS(=O)(=O)C=2C(=CC=3N(CC=4C(=CC=CC=4)I)N=CC=3C=2)F)=N1 UBGLVEIJGVQXPA-UHFFFAOYSA-N 0.000 claims 1
- BDXVDLWUWAYQKL-UHFFFAOYSA-N 6-fluoro-n-(6-fluoropyridin-2-yl)-1-[1-(1,2,3,4-tetrahydroisoquinolin-8-yl)ethyl]indazole-5-sulfonamide Chemical compound C=1C=CC=2CCNCC=2C=1C(C)N(C1=CC=2F)N=CC1=CC=2S(=O)(=O)NC1=CC=CC(F)=N1 BDXVDLWUWAYQKL-UHFFFAOYSA-N 0.000 claims 1
- QMJIVIHONRHYGL-UHFFFAOYSA-N 6-fluoro-n-(6-fluoropyridin-2-yl)-1-[1-(2-piperidin-4-ylphenyl)ethyl]indazole-5-sulfonamide Chemical compound N1=CC2=CC(S(=O)(=O)NC=3N=C(F)C=CC=3)=C(F)C=C2N1C(C)C1=CC=CC=C1C1CCNCC1 QMJIVIHONRHYGL-UHFFFAOYSA-N 0.000 claims 1
- SRBXSJAKGQJETP-UHFFFAOYSA-N 6-fluoro-n-(6-fluoropyridin-2-yl)-1-[1-[2-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]ethyl]indazole-5-sulfonamide Chemical compound N1=CC2=CC(S(=O)(=O)NC=3N=C(F)C=CC=3)=C(F)C=C2N1C(C)C1=CC=CC=C1C1=CCNCC1 SRBXSJAKGQJETP-UHFFFAOYSA-N 0.000 claims 1
- UFTKNJOJYUBCRR-UHFFFAOYSA-N 6-fluoro-n-(6-fluoropyridin-2-yl)-1-[[2-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]methyl]indazole-5-sulfonamide Chemical compound FC1=CC=CC(NS(=O)(=O)C=2C(=CC=3N(CC=4C(=CC=CC=4)C=4CCNCC=4)N=CC=3C=2)F)=N1 UFTKNJOJYUBCRR-UHFFFAOYSA-N 0.000 claims 1
- 241000277306 Esocidae Species 0.000 claims 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- OJFGKCLKLHOZNY-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-6-fluoro-1-(1,2,3,4-tetrahydroisoquinolin-8-ylmethyl)indazole-5-sulfonamide Chemical compound FC1=CC=2N(CC=3C=4CNCCC=4C=CC=3)N=CC=2C=C1S(=O)(=O)NC1=NC=C(Cl)S1 OJFGKCLKLHOZNY-UHFFFAOYSA-N 0.000 claims 1
- KVCFFRVMHFWXRQ-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-6-fluoro-1-[1-(1,2,3,4-tetrahydroisoquinolin-8-yl)ethyl]indazole-5-sulfonamide Chemical compound C=1C=CC=2CCNCC=2C=1C(C)N(C1=CC=2F)N=CC1=CC=2S(=O)(=O)NC1=NC=C(Cl)S1 KVCFFRVMHFWXRQ-UHFFFAOYSA-N 0.000 claims 1
- JXVAEAWLORTHQW-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-6-fluoro-2-[1-(1,2,3,4-tetrahydroisoquinolin-8-yl)ethyl]indazole-5-sulfonamide Chemical compound C=1C=CC=2CCNCC=2C=1C(C)N(N=C1C=C2F)C=C1C=C2S(=O)(=O)NC1=NC=C(Cl)S1 JXVAEAWLORTHQW-UHFFFAOYSA-N 0.000 claims 1
- CSCJDGKSKWJIBP-UHFFFAOYSA-N n-(6-fluoropyridin-2-yl)-6-methyl-1-[1-(1,2,3,4-tetrahydroisoquinolin-8-yl)ethyl]indazole-5-sulfonamide Chemical compound C=1C=CC=2CCNCC=2C=1C(C)N(C1=CC=2C)N=CC1=CC=2S(=O)(=O)NC1=CC=CC(F)=N1 CSCJDGKSKWJIBP-UHFFFAOYSA-N 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 150000003557 thiazoles Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261719118P | 2012-10-26 | 2012-10-26 | |
| US61/719,118 | 2012-10-26 | ||
| PCT/US2013/066360 WO2014066491A1 (en) | 2012-10-26 | 2013-10-23 | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015535252A JP2015535252A (ja) | 2015-12-10 |
| JP2015535252A5 true JP2015535252A5 (https=) | 2016-12-08 |
Family
ID=50545213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539755A Pending JP2015535252A (ja) | 2012-10-26 | 2013-10-23 | 電位作動型ナトリウムチャネルにおいて選択的活性を有するｎ−置換インダゾールスルホンアミド化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9388179B2 (https=) |
| EP (1) | EP2911663B1 (https=) |
| JP (1) | JP2015535252A (https=) |
| KR (1) | KR20150074123A (https=) |
| CN (1) | CN104869992A (https=) |
| AU (1) | AU2013334664A1 (https=) |
| BR (1) | BR112015008987A2 (https=) |
| CA (1) | CA2891056A1 (https=) |
| RU (1) | RU2015119640A (https=) |
| WO (1) | WO2014066491A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| RU2014121984A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств |
| CN104718188B (zh) | 2012-05-22 | 2018-08-21 | 基因泰克公司 | N-取代的苯甲酰胺类及其在治疗疼痛中的用途 |
| KR101663436B1 (ko) | 2012-07-06 | 2016-10-06 | 제넨테크, 인크. | N-치환된 벤즈아미드 및 이의 사용 방법 |
| RU2015143906A (ru) | 2013-03-14 | 2017-04-18 | Дженентек, Инк. | Замещенные триазолопиридины и способы их применения |
| BR112015023397A2 (pt) | 2013-03-15 | 2017-07-18 | Genentech Inc | benzoxazois substituídos e métodos de uso dos mesmos |
| WO2015078374A1 (en) | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| JP2017525677A (ja) | 2014-07-07 | 2017-09-07 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| US9783527B2 (en) * | 2014-09-16 | 2017-10-10 | Abbvie Inc. | Indazole ureas and method of use |
| CA2979534A1 (en) * | 2015-03-13 | 2016-09-22 | Abbvie Inc. | (indazol-4-yl)hexahydropyrrolopyrrolones and method of use |
| HK1252567A1 (zh) | 2015-05-22 | 2019-05-31 | 基因泰克公司 | 被取代的苯甲酰胺和其使用方法 |
| JP2018526371A (ja) | 2015-08-27 | 2018-09-13 | ジェネンテック， インコーポレイテッド | 治療化合物及びその使用方法 |
| CA2999769A1 (en) | 2015-09-28 | 2017-04-06 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| EP3380466A1 (en) | 2015-11-25 | 2018-10-03 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| AU2016370554B2 (en) | 2015-12-18 | 2018-11-29 | Merck Sharp & Dohme Corp. | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| EP3436432B1 (en) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| PL3458449T3 (pl) | 2016-05-20 | 2025-06-23 | Xenon Pharmaceuticals Inc. | Związki benzenosulfonamidowe i ich zastosowanie jako środki terapeutyczne |
| PE20190980A1 (es) | 2016-10-17 | 2019-07-09 | Genentech Inc | Compuestos terapeuticos y metodos para utilizarlos |
| CN110325531B (zh) | 2016-12-09 | 2022-05-27 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
| JP2020511511A (ja) | 2017-03-24 | 2020-04-16 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体 |
| CN107247885B (zh) * | 2017-07-06 | 2020-07-03 | 中国水产科学研究院黄海水产研究所 | 一种电压-门控钠离子通道的结构预测方法 |
| AR114263A1 (es) | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| US10947251B2 (en) | 2018-03-30 | 2021-03-16 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| US10745392B2 (en) | 2018-06-13 | 2020-08-18 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| KR20210054510A (ko) | 2018-08-31 | 2021-05-13 | 제논 파마슈티칼스 인크. | 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도 |
| MA53488A (fr) | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| WO2020192553A1 (zh) * | 2019-03-22 | 2020-10-01 | 上海海雁医药科技有限公司 | 磺酰基取代的苯并杂环甲酰胺衍生物、其制法与医药上的用途 |
| US12552797B2 (en) | 2019-11-27 | 2026-02-17 | Praxis Precision Medicines, Inc. | Process for making (3-[cyclopropylethoxy(difluoro)methyl]-6-6[5-fluoro-6-(2,2,2-trifluoroethoxy-3-pyridyl]- [1,2,4]triazolo[4,3-a]pyrazine |
| AR128499A1 (es) | 2022-02-14 | 2024-05-15 | Arase Therapeutics Inc | Inhibidores de parg |
| TW202345811A (zh) * | 2022-03-31 | 2023-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吲唑類化合物、其製備方法及其在醫藥上的應用 |
| MX2024013240A (es) | 2022-04-26 | 2024-12-06 | Praxis Prec Medicines Inc | Tratamiento de trastornos neurologicos |
| WO2024173234A1 (en) * | 2023-02-13 | 2024-08-22 | Arase Therapeutics Inc. | Inhibitors of parg |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3705185A (en) | 1969-04-14 | 1972-12-05 | Minnesota Mining & Mfg | N-aroyl sulfonamides |
| US4136256A (en) | 1977-09-27 | 1979-01-23 | American Cyanamid Company | 4-(monoalkylamino)benzoic acid imidates |
| US4309553A (en) | 1977-09-27 | 1982-01-05 | American Cyanamid Company | Aldehydes and ketones containing a 4-(monoalkylamino)-benzoyl substituent |
| US4242273A (en) | 1977-09-27 | 1980-12-30 | American Cyanamid Company | 4-(Monoalkylamino)benzoic acid amides and imidates |
| US4272546A (en) | 1977-12-19 | 1981-06-09 | American Cyanamid Company | Esters of 4-(monoalkylamino)benzoic hydroxyalkanoic acids |
| US4254138A (en) | 1977-12-19 | 1981-03-03 | American Cyanamid Company | Esters of 4-(monoalkylamino)benzoic hydroxyalkanoic acids |
| US4205085A (en) | 1978-03-09 | 1980-05-27 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino)phenyl compounds |
| US4243609A (en) | 1978-02-02 | 1981-01-06 | American Cyanamid Company | Ring-fluorinated 4-(hexadecyl-amino) N-substituted benzamide compounds |
| US4245097A (en) | 1978-02-27 | 1981-01-13 | American Cyanamid Company | 4-[(Monosubstituted-alkyl) amino] benzoic acids and analogs as hypolipidemic and antiatherosclerotic agents |
| US4230878A (en) | 1978-03-08 | 1980-10-28 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic 4-[(cyclopropyl alkyl)amino]benzoic acids and derivatives |
| US4230628A (en) | 1978-04-12 | 1980-10-28 | American Cyanamid Company | 4-[(Carboxyl- and sulfamyl-substituted alkyl)-amino] benzoic acids and analogs |
| US4211783A (en) | 1978-03-20 | 1980-07-08 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic novel 4-(aralkyl- and heteroarylalkylamino)phenyl compounds |
| US4227014A (en) | 1978-02-27 | 1980-10-07 | American Cyanamid Company | 4-[(Cycloalkyl or cycloalkenyl substituted)amino, alkylamino or alkenylamino]benzoic acids and salts thereof |
| US4305959A (en) | 1978-03-09 | 1981-12-15 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds |
| US4310545A (en) | 1978-03-09 | 1982-01-12 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino) phenyl compounds |
| US4318914A (en) | 1978-03-09 | 1982-03-09 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds |
| US4485105A (en) | 1978-10-12 | 1984-11-27 | American Cyanamid Company | Method of treating hyperlipidemia with 4-(monoalkylamino)benzoic acid amides |
| DK471479A (da) | 1978-12-13 | 1980-06-14 | Pfizer | Fremgangsmaade til fremstilling af imidazolderivater og salte deraf |
| US4670421A (en) | 1982-07-12 | 1987-06-02 | American Cyanamid Company | Antiatherosclerotic silanes |
| JP4316787B2 (ja) | 2000-01-11 | 2009-08-19 | 壽製薬株式会社 | エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、 |
| SE0402762D0 (sv) * | 2004-11-11 | 2004-11-11 | Astrazeneca Ab | Indazole sulphonamide derivatives |
| KR20080015102A (ko) * | 2005-05-10 | 2008-02-18 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널 조절인자로서의 바이사이클릭 유도체 |
| CA2693588C (en) * | 2007-07-13 | 2015-11-17 | Icagen, Inc. | Sodium channel inhibitors |
| EP2355659A4 (en) * | 2008-10-23 | 2012-10-10 | Merck Sharp & Dohme | Fused Hetereocyclic M1 Receptor Positive Allosmatic Modulators |
| HUE025013T2 (hu) | 2009-01-12 | 2016-04-28 | Pfizer Ltd | Szulfonamid-származékok |
| JP5872552B2 (ja) | 2010-07-09 | 2016-03-01 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化学化合物 |
| WO2012004714A2 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Chemical compounds |
| WO2012004743A1 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
| ES2532357T3 (es) | 2010-07-12 | 2015-03-26 | Pfizer Limited | Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor |
| EP2593433B1 (en) | 2010-07-12 | 2014-11-26 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| JP2013532185A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 化合物 |
| US9102621B2 (en) | 2010-07-12 | 2015-08-11 | Pfizer Limited | Acyl sulfonamide compounds |
| WO2012064984A1 (en) | 2010-11-10 | 2012-05-18 | Datalogic Scanning, Inc. | Adaptive data reader and method of operating |
| WO2012095781A1 (en) | 2011-01-13 | 2012-07-19 | Pfizer Limited | Indazole derivatives as sodium channel inhibitors |
| MX2014001851A (es) | 2011-08-17 | 2014-10-24 | Amgen Inc | Inhibidores del canal de heteroarilo sodio. |
| RU2014121984A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| EP2788332A1 (en) | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| US9051311B2 (en) | 2012-03-09 | 2015-06-09 | Amgen Inc. | Sulfamide sodium channel inhibitors |
-
2013
- 2013-10-23 JP JP2015539755A patent/JP2015535252A/ja active Pending
- 2013-10-23 AU AU2013334664A patent/AU2013334664A1/en not_active Abandoned
- 2013-10-23 CN CN201380068064.9A patent/CN104869992A/zh active Pending
- 2013-10-23 CA CA2891056A patent/CA2891056A1/en not_active Abandoned
- 2013-10-23 KR KR1020157013297A patent/KR20150074123A/ko not_active Withdrawn
- 2013-10-23 US US14/437,142 patent/US9388179B2/en active Active
- 2013-10-23 BR BR112015008987A patent/BR112015008987A2/pt not_active IP Right Cessation
- 2013-10-23 RU RU2015119640A patent/RU2015119640A/ru not_active Application Discontinuation
- 2013-10-23 WO PCT/US2013/066360 patent/WO2014066491A1/en not_active Ceased
- 2013-10-23 EP EP13849733.4A patent/EP2911663B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015535252A5 (https=) | ||
| RU2015119640A (ru) | Соединения n-замещенного индазол-сульфонамида с избирательной активностью в потенциал-зависимых натриевых каналах | |
| ES2535290T3 (es) | Compuestos de isoindolina sustituidos en posición 5 | |
| US10596180B2 (en) | Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl) oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same | |
| AU2018358160B2 (en) | Modulators of the integrated stress pathway | |
| KR102566924B1 (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| ES2726946T3 (es) | Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas | |
| JP5886411B2 (ja) | 新規のピリミジン誘導体 | |
| AU2018360850A1 (en) | Modulators of the integrated stress pathway | |
| JP2004521095A5 (https=) | ||
| CA3080808A1 (en) | Modulators of the integrated stress pathway | |
| RU2013143028A (ru) | Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ | |
| JP2006515858A5 (https=) | ||
| RU2000105266A (ru) | Производные 1-(n-фениламиноалкил)-пиперазина, замещенные в положении 2 фенильного кольца | |
| CA2430579A1 (en) | Isoindolin-1-one glucokinase activators | |
| RU2003120512A (ru) | Активаторы изоиндолин-1-он-глюкокиназы | |
| TW201922251A (zh) | 抗癌劑 | |
| ES2768399T3 (es) | Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida | |
| RU99100277A (ru) | Производные тиазола | |
| CN101578277A (zh) | 5-取代的异二氢吲哚化合物 | |
| EA200701680A1 (ru) | Лекарственная форма для перорального введения, содержащая розиглитазон | |
| JP2025512963A (ja) | ケモカイン受容体モジュレータ及びその使用 | |
| RU2018107581A (ru) | Новые ингибиторы cdk8/19 | |
| US20260098035A1 (en) | Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same | |
| JP2012519668A5 (https=) |